RxDoctor Payments Data

Misha Kucherov, MD

Psychiatry · Poughkeepsie, NYNPI 1821158163

Payments from drug & device makers

$33,399in general payments, 2019–2025

Across 1,551 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Biogen$2K
  • Lilly USA, LLC$1K
  • Harmony Biosciences LLC$1K
  • SK Life Science, Inc.$1K
  • EMD Serono, Inc.$1K
  • plus $21K from 54 others

What the payments were for

  • Travel & lodging$2661%
  • Food & beverage$32,21396%
  • Education$9203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)244$5,040
Biogen116$1,856
Lilly USA, LLC84$1,415
Harmony Biosciences LLC44$1,213
SK Life Science, Inc.60$1,213
EMD Serono, Inc.39$1,211
Novartis71$1,195
Amgen(2 entities)43$1,062
Eisai Inc.39$941
Teva Pharmaceuticals USA, Inc.34$921
AstraZeneca(2 entities)32$916
Jazz Pharmaceuticals Inc.45$871
UCB, Inc.41$751
Amneal Pharmaceuticals LLC40$745
Alnylam Pharmaceuticals Inc.24$722
Pfizer41$677
Scilex Pharmaceuticals Inc.42$646
Livanova USA, Inc.7$634
Neurocrine Biosciences, Inc.29$628
Johnson & Johnson(2 entities)17$613
Lundbeck LLC20$557
Genentech USA, Inc.30$535
TG Therapeutics, Inc.17$529
Avanir Pharmaceuticals, Inc.22$527
Collegium Pharmaceutical, Inc.30$510
Neurelis, Inc.16$408
ANI Pharmaceuticals, Inc.8$384
Acadia Pharmaceuticals Inc22$379
Kyowa Kirin, Inc.18$359
GSK11$357
Catalyst Pharmaceuticals, Inc.17$343
Novo Nordisk14$327
Sunovion Pharmaceuticals Inc.20$306
Otsuka America Pharmaceutical, Inc.10$296
Argenx US, Inc.10$294
Axsome Therapeutics, Inc.14$259
Bristol Myers Squibb17$239
Arbor Pharmaceuticals, Inc.15$234
E.r. Squibb & Sons, L.L.C.2$233
Grifols USA, LLC12$227
Impel Pharmaceuticals Inc.6$203
Exact Sciences7$198
Medtronic3$168
Merck10$159
Biohaven Pharmaceutical Holding Company Ltd.7$147
Biohaven Pharmaceuticals, Inc.10$133
Supernus Pharmaceuticals, Inc.8$126
Portola Pharmaceuticals, LLC2$119
Alkermes, Inc.1$115
Adamas Pharmaceuticals, Inc.5$112
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$108
Endo Pharmaceuticals Inc.6$107
Currax Pharmaceuticals LLC8$105
Orexo US, Inc.4$81
Greenwich Biosciences, Inc.4$71
MDD US Operations, LLC4$68
Sanofi3$66
Biodelivery Sciences International, Inc.4$57
Kowa Pharmaceuticals America, Inc.4$55
Acorda Therapeutics, Inc3$54

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,399 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$559,135
Medicare patients
743
Services billed
7,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel258$283,600
IngrezzaValbenazine Tosylate22$200,933
VumerityDiroximel Fumarate16$160,311
Nurtec OdtRimegepant Sulfate46$84,972
UbrelvyUbrogepant27$67,727
BriviactBrivaracetam30$44,160
NourianzIstradefylline20$40,616
AptiomEslicarbazepine Acetate24$37,071
Dimethyl Fumarate11$27,039
Xtampza ErOxycodone Myristate25$22,655
Levetiracetam646$21,327
Lacosamide138$21,003
OxycontinOxycodone Hcl28$20,020
BelsomraSuvorexant46$19,908
ZtlidoLidocaine35$18,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$941$283,600258 claims
Neurocrine Biosciences, Inc.Ingrezza$628$200,93322 claims
BiogenVumerity$1,856$160,31116 claims
PfizerNurtec Odt, Lyrica, Eliquis$677$103,44870 claims
AbbVieUbrelvy, Linzess$5,040$74,51338 claims
UCB, Inc.Briviact$751$44,16030 claims
Kyowa Kirin, Inc.Nourianz$359$40,61620 claims
Sunovion Pharmaceuticals Inc.Aptiom$306$37,07124 claims
Collegium Pharmaceutical, Inc.Xtampza Er$510$22,65525 claims
MerckBelsomra$159$19,90846 claims
Scilex Pharmaceuticals Inc.Ztlido$646$18,15635 claims
Lilly USA, LLCMounjaro$1,415$12,16515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →